🇺🇸 FDA
Pipeline program

velaglucerase alfa

HGT-GCB-068

Phase 2 mab completed

Quick answer

velaglucerase alfa for Gaucher Disease, Type 3 is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Gaucher Disease, Type 3
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials